The iShares US Pharmaceuticals ETF has an implied analyst target price of $109.89 per unit based on its underlying holdings, representing a 9.68% upside from its recent trading price near $100.19. Three holdings with notable upside potential are Crinetics Pharmaceuticals, CorMedix, and Zoetis, which together account for 5.04% of the ETF. Crinetics Pharmaceuticals has an average analyst target of $83.14 per share, 97.82% above its recent price of $42.03. CorMedix has a target of $14.00, implying 59.27% upside from $8.79, while Zoetis is expected to reach $114.12, a 51.32% increase from $75.42.
CorMedix IncAnalyst price target implies 59.27% upside from current price.
Zoetis IncAnalyst price target implies 51.32% upside from current price.
Crinetics Pharmaceuticals IncAnalyst price target implies 97.82% upside from current price.